National Institute of Neurological Disorders and Stroke (NINDS)
Share this
Related Posts
-
Hippocampal Volume as an Enrichment Biomarker in Trials of Patients with Mild Cognitive Impairment -
Facilitating rapid data and information sharing by establishing a sustainable, integrated, and standardized platform advancing knowledge to enable expedited drug development
-
Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments
-
“Improving Clinical Trials to Deliver Better Treatments,” as featured in the Spring 2018 edition of “Progress, the research magazine of Parkinson’s UK” -
New Collaboration Seeks to Speed Huntington’s Disease Drug Licensing